摘要
目的分析慢性心力衰竭(CHF)应用沙库巴曲缬沙坦治疗的临床效果。方法80例CHF患者,随机分为对照组与观察组,各40例。对照组予以CHF患者吸氧、抗感染、利尿等常规治疗,观察组在对照组治疗基础上辅助沙库巴曲缬沙坦治疗。对比两组患者临床疗效、不良反应发生情况及治疗前后血浆氨基末端脑钠肽前体(NT-proBNP)水平、心功能[左心室射血分数(LVEF)、左心室收缩末期内径(LVESD)、左心室舒张末期内径(LVEDD)]改善情况。结果治疗后,观察组的治疗总有效率92.50%高于对照组的72.50%,差异具有统计学意义(P<0.05)。治疗后,观察组的不良反应发生率为10.00%与对照组的7.50%对比,差异无统计学意义(P>0.05)。治疗后,观察组患者的LVEF、LVESD、LVEDD、NT-proBNP水平均优于对照组,差异均具有统计学意义(P<0.05)。结论在吸氧、抗感染、利尿等常规治疗的基础上辅助沙库巴曲缬沙坦治疗CHF患者,可促进心功能改善,在延缓患者病情进展的基础上提升疾病治疗效果,且安全性理想。
Objective To analyze the clinical effect of chronic heart failure(CHF)and evaluate the feasibility of sacubitril and valsartan treatment.Methods A total of 80 CHF patients were randomly divided into control group and observation group,with 40 cases in each group.The control group received conventional treatments of oxygen inhalation,anti-infection and diuresis,and the observation group received sacubitril and valsartan on the basis of the control group.The clinical efficacy,occurrence of adverse reactions,and N-terminal pro-brain natriuretic peptide(NT-proBNP)and cardiac function[left ventricular ejection fraction(LVEF),left ventricular end-systolic diameter(LVESD),left ventricular end-diastolic diameter(LVEDD)]were compared between the two groups.Results After treatment,the total effective rate of the observation group was 92.50%,which was higher than 72.50%of the control group,and the difference was statistically significant(P<0.05).After treatment,the incidence of adverse reactions of the observation group was 10.00%,which had no statistically significant compared with 7.50%of the control group(P>0.05).After treatment,the levels of LVEF,LVESD,LVEDD and NT-proBNP of the observation group was better than that of the control group,and the difference was statistically significant(P<0.05).Conclusion On the basis of conventional treatments of oxygen inhalation,antiinfection and diuresis,adjuvant sacubitril and valsartan in the treatment of CHF can promote the improvement of cardiac function and improve the therapeutic effect of disease on the basis of delaying the progress of the disease,and the safety is ideal.
出处
《中国现代药物应用》
2021年第6期116-118,共3页
Chinese Journal of Modern Drug Application
关键词
沙库巴曲缬沙坦
慢性心力衰竭
治疗效果
心功能
不良反应
血浆氨基末端脑钠肽前体水平
Sacubatril and valsartan
Chronic heart failure
Therapeutic effect
Cardiac function
Adverse reactions
Plasma N-terminal pro-brain natriuretic peptide level
